Elicio Therapeutics (ELTX) EBIT (2020 - 2026)
Elicio Therapeutics posted quarterly EBIT of -$10.6 million for Q1 2026, up 1.25% year-on-year from -$10.5 million in Q1 2025, and down 19.9% on a QoQ basis from -$8.8 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of EBIT data on file, last reported at -$10.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 1.25% year-over-year to -$10.6 million; the trailing twelve-month figure through Mar 2026 stood at -$37.6 million (up 17.37% YoY), and the FY2025 full-year result was -$37.7 million, up 16.17% from the prior year.
- EBIT for Q1 2026 stood at -$10.6 million, down from -$8.8 million in the prior quarter.
- Across five years, EBIT topped out at -$5.8 million in Q3 2022 and bottomed at -$14.5 million in Q1 2022.
- The 5-year median for EBIT is -$10.1 million (2025), against an average of -$9.5 million.
- Peak annual rise in EBIT reached 65.84% in 2022, while the deepest fall reached 140.73% in 2022.
- A 5-year view of EBIT shows it stood at -$6.0 million in 2022, then plunged by 57.56% to -$9.4 million in 2023, then plunged by 43.48% to -$13.5 million in 2024, then soared by 34.39% to -$8.8 million in 2025, then slipped by 19.9% to -$10.6 million in 2026.
- The last three EBIT figures came in at -$10.6 million (Q1 2026), -$8.8 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -10.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.60 Mn |
| Dec 31, 2025 | -8.84 Mn |
| Sep 30, 2025 | -8.05 Mn |
| Jun 30, 2025 | -10.09 Mn |
| Mar 31, 2025 | -10.74 Mn |
| Dec 31, 2024 | -13.48 Mn |
| Sep 30, 2024 | -10.34 Mn |
| Jun 30, 2024 | -10.92 Mn |
| Mar 31, 2024 | -10.24 Mn |
| Dec 31, 2023 | -9.39 Mn |
| Sep 30, 2023 | -10.77 Mn |
| Jun 30, 2023 | -7.78 Mn |
| Mar 31, 2023 | -7.81 Mn |
| Dec 31, 2022 | -5.96 Mn |
| Sep 30, 2022 | -5.77 Mn |
| Jun 30, 2022 | -6.23 Mn |
| Mar 31, 2022 | -14.49 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | -15.76 Mn |
| Jun 30, 2021 | -18.24 Mn |
| Mar 31, 2021 | -19.94 Mn |
| Dec 31, 2020 | -13.85 Mn |
| Sep 30, 2020 | -11.59 Mn |
| Jun 30, 2020 | -17.27 Mn |
| Mar 31, 2020 | -12.57 Mn |